Skip to main content
SpringerLink
Log in

Infectious Microecology in Urinary Tract and Reproductive System

  • Chapter
Infectious Microecology

Part of the book series: Advanced Topics in Science and Technology in China ((ATSTC))

Abstract

Urinary tract infection (UTI) is an infection involving the kidneys, ureters, bladder, or urethra. These are the structures that urine passes through before being eliminated from the body. Symptoms include frequent feeling and/or need to urinate, pain during urination, and cloudy urine. The most common type of UTI is acute cystitis often referred to as bladder infection. An infection of the upper urinary tract or kidney is known as pyelonephritis, and is potentially more serious. Although they cause discomfort, UTI can usually be easily treated with a short course of antibiotics with no significant difference between the classes of antibiotics commonly used.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Liang C Z, Li H J, Wang Z P, et al. Treatment of chronic prostatitis in Chinese men. Asian J Androl. 2009. 11: 153–156.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Weidner W, Wagenlehner F M, Marconi M, et al. Acute bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: Andrological implications. Andrologia, 2008, 40: 105–112.

    Article  CAS  PubMed  Google Scholar 

  3. Nickel JC, Downey J, Johnston B, et al. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: A prospective multicenter clinical trial. J Urol, 2001, 165: 1539–1544.

    Article  CAS  PubMed  Google Scholar 

  4. Doble A. Chronic prostatitis. Br J Urol, 1994, 74: 537–541.

    Article  CAS  PubMed  Google Scholar 

  5. Krieger J N, Nyberg L Jr, Nickel J C. NIH consensus definition and classification of prostatitis. JAMA, 1999, 282: 236–237.

    Article  CAS  PubMed  Google Scholar 

  6. Weidner W, Anderson R U. Evaluation of acute and chronic bacterial prostatitis and diagnostic management of chronic prostatitis/chronic pelvic pain syndrome with special reference to infection/inflammation. Int J Antimicrob Agents, 2008, 31: S91–S95.

    Article  Google Scholar 

  7. Turner J A, Ciol M A, Von Korff M, et al. Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. J Urol, 2003, 169: 580–583.

    Article  PubMed  Google Scholar 

  8. Propert K J, Litwin M S, Wang Y, et al. Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res, 2006, 15: 299–305.

    Article  CAS  PubMed  Google Scholar 

  9. Clemens J Q, Calhoun E A, Litwin M S, et al. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology, 2009, 74: 983–987.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Collins M M, Stafford R S, O’Leary M P, et al. How common is prostatitis? A national survey of physician visits. J Urol, 1998, 159: 1224–1228.

    Article  CAS  PubMed  Google Scholar 

  11. Nickel J C, Downey J, Hunter D, et al. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol, 2001, 165: 842–845.

    Article  CAS  PubMed  Google Scholar 

  12. Roberts R O, Lieber M M, Rhodes T, et al. Prevalence of a physician-assigned diagnosis of prostatitis: The olmsted county study of urinary symptoms and health status among men. Urology, 1998, 51: 578–584.

    Article  CAS  PubMed  Google Scholar 

  13. Calhoun E A, McNaughton Collins M, Pontari M A, et al. The economic impact of chronic prostatitis. Arch Intern Med, 2004, 164: 1231–1236.

    Article  PubMed  Google Scholar 

  14. Krieger J N. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol Nefrol, 2004, 56: 99–107.

    CAS  PubMed  Google Scholar 

  15. McNaughton C M, Pontari M A, O’Leary M P, et al. Quality of life is impaired in men with chronic prostatitis: The chronic prostatitis collaborative research network. j gen intern med, 2001, 16: 656–662.

    Article  Google Scholar 

  16. Turner J A, Ciol M A, Von Korff M, et al. Health concerns of patients with nonbacterial prostatitis/pelvic pain. Arch Intern Med, 2005, 165: 1054–1059.

    Article  PubMed  Google Scholar 

  17. Fair W R, Parrish R F. Antibacterial substances in prostatic fluid. Prog Clin Biol Res, 1981, 75A: 247–264.

    Google Scholar 

  18. Johnson J R, Kuskowski M A, Gajewski A, et al. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis, 2005, 191: 46–50.

    Article  PubMed  Google Scholar 

  19. Millan-Rodriguez F, Palou J, Bujons-Tur A, et al. Acute bacterial prostatitis: Two different sub-categories according to a previous manipulation of the lower urinary tract. World J Urol, 2006, 24: 45–50.

    Article  PubMed  Google Scholar 

  20. Ozden E, Bostanci Y, Yakupoglu K Y, et al. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology, 2009, 74: 119–123.

    Article  PubMed  Google Scholar 

  21. Nickel J C, Olson M E, Barabas A, et al. Pathogenesis of chronic bacterial prostatitis in an animal model. Br J Urol, 1990, 66: 47–54.

    Article  CAS  PubMed  Google Scholar 

  22. Nickel J C, MoonT. Chronic bacterial prostatitis: An evolving clinical enigma. Urology, 2005, 66: 2–8.

    Article  PubMed  Google Scholar 

  23. Etienne M, Pestel-Caron M, Chavanet P, et al. Performance of the urine leukocyte esterase and nitrite dipstick test for the diagnosis of acute prostatitis. Clin Infect Dis, 2008, 46: 951–953.

    Article  PubMed  Google Scholar 

  24. Zegarra Montes L Z, Sanchez Mejia A A, Loza Munarriz C A, et al. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int Braz J Urol, 2008, 34: 30–37; discussion, 38–40.

    Article  PubMed  Google Scholar 

  25. Magri V, Wagenlehner F M, Montanari E, et al. Semen analysis in chronic bacterial prostatitis: Diagnostic and therapeutic implications. Asian J Androl, 2009, 11: 461–477.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Budia A, Luis Palmero J, Broseta E, et al. Value of semen culture in the diagnosis of chronic bacterial prostatitis: A simplified method. Scand J Urol Nephrol, 2006, 40: 326–331.

    Article  PubMed  Google Scholar 

  27. Rizzo M, Marchetti F, Travaglini F, et al. Prevalence, diagnosis and treatment of prostatitis in Italy: A prospective urology outpatient practice study. BJU Int, 2003, 92: 955–959.

    Article  CAS  PubMed  Google Scholar 

  28. McNaughton C M, Fowler F JJr, Elliott DB, et al. Diagnosing and treating chronic prostatitis: Do urologists use the four-glass test? Urology, 2000, 55: 403–407.

    Article  Google Scholar 

  29. Nickel J C, Shoskes D, Wang Y, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol, 2006, 176: 119–124.

    Article  PubMed  Google Scholar 

  30. Schaeffer A J, Knauss J S, Landis J R, et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study. J Urol, 2002, 168: 1048–1053.

    Article  PubMed  Google Scholar 

  31. Nickel J C. Clinical evaluation of the patient presenting with prostatitis. Eur Urol, 2003, 2: 11–14.

    Article  Google Scholar 

  32. Lee J C, Muller C H, Rothman I, et al. Prostate biopsy culture findings of men with chronic pelvic pain syndrome do not differ from those of healthy controls. J Urol, 2003, 169: 584–587; discussion 587–588.

    Article  PubMed  Google Scholar 

  33. Wise G J, Shteynshlyuger A. Atypical infections of the prostate. Curr Prostate Rep, 2008, 6: 86–93.

    Article  Google Scholar 

  34. Schaeffer A J, Wu S C, Tennenberg A M, et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol, 2005, 174: 161–164.

    Article  CAS  PubMed  Google Scholar 

  35. Krieger J N, Ross S O, Limaye A P, et al. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology, 2005, 66: 721–725.

    Article  PubMed  Google Scholar 

  36. Naber K G Management of bacterial prostatitis: What’s new? BJU Int, 2008, 101: S7-S10.

    Article  PubMed  Google Scholar 

  37. Naber K G, Roscher K, Botto H, et al. Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents, 2008, 32: 145–153.

    Article  CAS  PubMed  Google Scholar 

  38. Nickel J C, Xiang J. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. J Urol, 2008, 179: 1391–1395.

    Article  PubMed  Google Scholar 

  39. Szoke I, Torok L, Dosa E, et al. The possible role of anaerobic bacteria in chronic prostatitis. Int J Androl, 1998, 21: 163–168.

    Article  CAS  PubMed  Google Scholar 

  40. Skerk V, Krhen I, Schonwald S, et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents, 2004, 24: S53-S56.

    Article  CAS  Google Scholar 

  41. Charalabopoulos K, Karachalios G, Baltogiannis D, et al. Penetration of antimicrobial agents into the prostate. Chemotherapy, 2003, 49: 269–279.

    Article  CAS  PubMed  Google Scholar 

  42. Naber K G, Sorgel F. Antibiotic therapy-rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia, 2003, 35: 331–335.

    Article  CAS  PubMed  Google Scholar 

  43. Wagenlehner F M, Weidner W, Sorgel F, et al. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents, 2005, 26: 1–7.

    Article  CAS  PubMed  Google Scholar 

  44. Shigehara K, Miyagi T, Nakashima T, et al. Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis. J Infect Chemother, 2008, 14: 40–43.

    Article  PubMed  Google Scholar 

  45. Etienne M, Chavanet P, Sibert L, et al. Acute bacterial prostatitis: Heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis, 2008, 8: 12.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Ha U S, Kim M E, Kim C S, et al. Acute bacterial prostatitis in Korea: Clinical outcome, including symptoms, management, microbiology and course of disease. Int J Antimicrob Agents, 2008, 31: S96–S101.

    Article  Google Scholar 

  47. Magri V, Trinchieri A, Pozzi G, et al. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob Agents, 2007, 29: 549–556.

    Article  CAS  PubMed  Google Scholar 

  48. de la Rosette J J, Hubregtse M R, Meuleman E J, et al. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology, 1993, 41: 301–307.

    Article  CAS  PubMed  Google Scholar 

  49. Nickel J C. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents, 2008, 31: S112–S116.

    Article  PubMed Central  Google Scholar 

  50. Kurzer E, Kaplan S. Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. Eur Urol, 2002, 42: 163–166.

    Article  CAS  PubMed  Google Scholar 

  51. Murphy A B, Macejko A, Taylor A, Nadler R B. Chronic prostatitis: management strategies. Drugs, 2009, 69: 71–84.

    Article  CAS  PubMed  Google Scholar 

  52. El-Hakim A, Shah D K, Smith A D. Advanced therapy for prostatitis: Minimally invasive and invasive therapies. Curr Urol Rep, 2003, 1: 44–50.

    Google Scholar 

  53. Nickel J C, Downey J, Ardem D, et al. Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol, 2004, 172: 551–554.

    Article  PubMed  Google Scholar 

  54. Juricic C, F. K K, Sietzen W, et al. Concentration of amoxicillin and clavulanate in the prostate tissue and in serum: A pharmacokinetic study. Proceedings of the 15th International Congress of Chemotherapy, 1987.

    Google Scholar 

  55. Fraschini F, Scaglione F, Falchi M, et al. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother, 1990, 2: 171–177.

    CAS  PubMed  Google Scholar 

  56. Klotz T, Braun M, Bin Saleh A, et al. Penetration of a single infusion of ampicillin and sulbactam into prostatic tissue during transurethral prostatectomy. Int Urol Nephrol, 1999, 31: 203–209.

    Article  CAS  PubMed  Google Scholar 

  57. Goto T, Makinose S, Ohi Y, et al. Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol, 1998, 5: 243–246.

    Article  CAS  PubMed  Google Scholar 

  58. Symes J M, Jarvis J D, Tresidder G C. An appraisal of cephalexin monohydrate levels in semen and prostatic tissue. Chemotherapy, 1974, 20: 257–262.

    Article  CAS  PubMed  Google Scholar 

  59. Litvak A S, Franks C D, Vaught S K, et al. Cefazolin and cephalexin levels in prostatic tissue and sera. Urology, 1976, 7: 497–499.

    Article  CAS  PubMed  Google Scholar 

  60. Smith R P, Schmid G P, Baltch A L, et al. Concentration of cefaclor in human prostatic tissue. Am J Med Sci, 1981, 281: 19–24.

    Article  CAS  PubMed  Google Scholar 

  61. Vree T B, Hekster Y A. Pharmacokinetics and tissue concentrations of cefuroxime. Pharm Weekbl Sci, 1990, 12: 262–266; discussion 267.

    Article  CAS  PubMed  Google Scholar 

  62. Becopoulos T, Georgoulias D, Constantinides C, et al. Acute prostatitis: which antibiotic to use first. J Chemother, 1990, 2: 244–246.

    CAS  PubMed  Google Scholar 

  63. Adam D, Schalkhauser K, Boettger F. Diffusion of cefuroxime into the prostatic and other tissues of the urogenital region [in German]. Med Klin, 1979, 74: 1867–1870.

    CAS  PubMed  Google Scholar 

  64. Fraschini F, Scaglione F, Mezzetti M, et al. Pharmacokinetic profile of cefotetan in different clinical conditions. Drugs Under Experimental and Clinical Research, 1988, 14: 547–553.

    CAS  PubMed  Google Scholar 

  65. Takeuchi N, Kinukawa T, Matsuura O, et al. A study of prostatic tissue levels of latamoxef, cefoperazone and cefotaxime [in Japanese]. Hinyokika Kiyo, 1986, 32: 1831–1841.

    CAS  PubMed  Google Scholar 

  66. Fujita K, Fujita H M, Fujii K, et al. Cefotaxime concentration in the prostatic tissue [in Japanese]. Jpn J Antibiot, 1983, 36: 1465–1468.

    CAS  PubMed  Google Scholar 

  67. Novick W J Jr. Levels of cefotaxime in body fluids and tissues: A review. Rev Infect Dis, 1982, 4: S346-S353.

    Article  Google Scholar 

  68. Martin C, Viviand X, Cottin A, et al. Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy. Antimicrob Agents Chemother, 1996, 40:1311–1313.

    PubMed Central  CAS  PubMed  Google Scholar 

  69. Morita M, Hatakeyama T, Suzuki K. Ceftazidime concentration in human prostatic tissue and serum following intravenous injection]. Hinyokika Kiyo, 1991, 37: 659–662.

    CAS  PubMed  Google Scholar 

  70. Morita M, Nakagawa H, Suzuki K. Cefixime concentration in human prostatic tissue following 3-days of administration [in Japanese]. Hinyokika Kiyo, 1991, 37: 1581–1584.

    CAS  PubMed  Google Scholar 

  71. Naber K G, Kinzig M, Adam D, et al. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue. Infection, 1991, 19: 30–35.

    Article  CAS  PubMed  Google Scholar 

  72. Madsen P O, Dhruv R, Friedhoff L T. Aztreonam concentrations in human prostatic tissue. Antimicrob Agents Chemother, 1984, 26: 20–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Whitby M, Hempenstall J, Gilpin C, et al. Penetration of monobactam antibiotics (aztreonam, carumonam) into human prostatic tissue. Chemotherapy, 1989, 35: 7–11.

    Article  CAS  PubMed  Google Scholar 

  74. Cannon G M Jr., Smaldone M C, Paterson D L. Extended-spectrum betalactamase gram-negative sepsis following prostate biopsy: Implications for use of fluoroquinolone prophylaxis. Can J Urol, 2007, 14: 3653–3655.

    PubMed  Google Scholar 

  75. Baker S D, Horger D C, Keane T E. Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess. Urology, 2004, 64: 808–810.

    Article  PubMed  Google Scholar 

  76. Pierce JR Jr., Saeed Q, Davis WR. Prostatic abscess due to community acquired methicillin-resistant Staphylococcus aureus. Am J Med Sci, 2008, 335: 154–156.

    Article  PubMed  Google Scholar 

  77. Bergmann M, Lederer B, Takacs F. Tissue concentrations of sulfametroltrimethoprim in the human prostate [in German]. Urologe A, 1979, 18: 335–337.

    CAS  PubMed  Google Scholar 

  78. Dan M, Golomb J, Gorea A, et al. Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother, 1986, 30: 88–89.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Naber C K, Steghafner M, Kinzig-Schippers M, et al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother, 2001, 45: 293–297.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Drusano G L, Preston S L, Van Guilder M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother, 2000, 44: 2046–2051.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  81. Wagenlehner F M, Kees F, Weidner W, et al. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int J Antimicrob Agents, 2008, 31: 21–26.

    Article  CAS  PubMed  Google Scholar 

  82. Wagenlehner F M, Lunz J C, Kees F, et al. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. J Chemother, 2006, 18: 485–489.

    Article  CAS  PubMed  Google Scholar 

  83. Naber K G, Adam D, Kees F. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. Drugs, 1987, 34: S44–550.

    Article  CAS  PubMed  Google Scholar 

  84. Giberti C, Gallo F, Rosignoli M T, et al. Penetration of orally administered prulifloxacin into human prostate tissue. Clin Drug Investig, 2009, 29: 27–34.

    Article  CAS  PubMed  Google Scholar 

  85. Foulds G, Madsen P, Cox C, et al. Concentration of azithromycin in human prostatic tissue. Eur J Clin Microbiol Infect Dis, 1991, 10: 868–871.

    Article  CAS  PubMed  Google Scholar 

  86. Giannopoulos A, Koratzanis G, Giamarellos-Bourboulis E J, et al. Pharmacokinetics of clarithromycin in the prostate: Implications for the treatment of chronic abacterial prostatitis. J Urol, 2001, 165: 97–99.

    Article  CAS  PubMed  Google Scholar 

  87. Grabe M, Bishop M C, Bjerklund-Johansen L, et al. Management of urinary and male genital tract infections. European Association of Urology, 2008: 84–88.

    Google Scholar 

  88. Cai T, Mazzoli S, Bechi A, et al. Serenoa repens associated with Urticadioica (ProstaMEV)and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: Results from a prospective randomised study. Int J Antimicrob Agents, 2009, 33: 549–553.

    Article  CAS  PubMed  Google Scholar 

  89. Jeong C W, Lim D J, Son H, et al. Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urol Int, 2008, 80: 157–161.

    Article  CAS  PubMed  Google Scholar 

  90. Giannarini G, Mogorovich A, Valent F, et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: A prospective, randomized, double-blind trial. J Chemother, 2007, 19: 304–308.

    Article  CAS  PubMed  Google Scholar 

  91. Magri V, Trinchieri A, Ceriani I, et al. Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome. Arch Ital Urol Androl, 2007, 79: 93–98.

    PubMed  Google Scholar 

  92. Chen W M, Yang C R, Ou Y C, et al. Combination regimen in the treatment of chronic prostatitis. Arch Androl, 2006, 52: 117–121.

    Article  CAS  PubMed  Google Scholar 

  93. Ziaee A M, Akhavizadegan H, Karbakhsh M. Effect of allopurinol in chronic nonbacterial prostatitis: A double blind randomized clinical trial. Int Braz J Urol, 2006, 32: 181–186.

    Article  PubMed  Google Scholar 

  94. Alexander R B, Propert K J, Schaeffer A J, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: A randomized, double-blind trial. Ann Intern Med, 2004, 141: 581–589.

    Article  CAS  PubMed  Google Scholar 

  95. Nickel J C, Downey J, Clark J, et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: A randomized placebo-controlled multicenter trial. Urology, 2003, 62: 614–617.

    Article  PubMed  Google Scholar 

  96. Bundrick W, Heron S P, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: A randomized doubleblind multicenter study. Urology, 2003, 62: 537–541.

    Article  PubMed  Google Scholar 

  97. Naber K G Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents, 2002, 20: 18–27.

    Article  CAS  PubMed  Google Scholar 

  98. Hu W L, Zhong S Z, He H X. Treatment of chronic bacterial prostatitis with amikacin through anal submucosal injection. Asian J Androl, 2002, 4: 163–167.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China

    Zhoujun Shen, Shan Zhong, Yu Zhu, Yuan Shao, Wei He, Chenjing Zhang, Xianjin Wang, Tao Li,  Sakaliya & Hongchao He

Authors
  1. Zhoujun Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shan Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuan Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chenjing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xianjin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sakaliya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hongchao He
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China

    Lanjuan Li

  2. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, China

    Lanjuan Li

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Shen, Z. et al. (2014). Infectious Microecology in Urinary Tract and Reproductive System. In: Li, L. (eds) Infectious Microecology. Advanced Topics in Science and Technology in China. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43883-1_14

Download citation

Publish with us

Policies and ethics

Search

Navigation